Posted by Michael Wonder on 10 Nov 2021
Merck and Ridgeback announce Japanese Government to purchase 1.6 million courses of molnupiravir, an investigational oral COVID-19 anti-viral medicine, upon authorisation or approval
10 November 2021 - Merck and Ridgeback Biotherapeutics today announced that the Japanese government will purchase, upon authorization or approval, approximately 1.6 million courses of molnupiravir (MK-4482, EIDD-2801), an investigational oral anti-viral medicine.
Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.
Merck’s applications for the potential authorised use of molnupiravir are under review by Japan’s Pharmaceuticals and Medical Devices Agency, the U.S. FDA and the EMA.
